JOINT FILING AGREEMENT
Exhibit 99.1
This Joint Filing Agreement, dated as of November 20, 2017, is by and among Xxxxxx Capital Partners II L.P., Xxxxxx Capital LLC, Xxxxxx Capital Management LLC, Xxxxxx Capital Management L.P. and Xxxxx Xxxxxx (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G/A and/or 13D with respect to shares of Common Stock, $0.001 par value per share, of Keryx Biopharmaceuticals, Inc. that may be beneficially owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G/A and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice (or such lesser period of notice as the Filers may mutually agree) to the other party. Executed and delivered as of the date first above written.
Date: November 20, 2017
|
XXXXXX CAPITAL PARTNERS II, L.P.
|
|
|
By: Xxxxxx Capital, LLC,
|
|
|
its General Partner
|
|
|
By: /s/ Xxxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx, Managing Member
|
|
|
XXXXXX CAPITAL, LLC
|
|
|
By: /s/ Xxxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx, Managing Member
|
|
|
XXXXXX CAPITAL MANAGEMENT, LLC
|
|
|
By: /s/ Xxxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx, Managing Member
|
|
|
XXXXXX CAPITAL MANAGEMENT, L.P.
|
|
|
By: Xxxxxx Capital Management, LLC,
|
|
|
its General Partner
|
|
|
By: /s/ Xxxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx, Managing Member
|
|
|
XXXXX XXXXXX
|
|
|
By: /s/ Xxxxx Xxxxxx
|
|
|
Xxxxx Xxxxxx, individually
|
